CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Drugs.com New Drug Applications
High ImpactOriginal article

Ascelia Pharma Provides Update on the Orviglance NDA

NDA FilingCRLOrviglanceNegative
AI Analysis

Summary

Ascelia Pharma announced receipt of a Complete Response Letter from the FDA regarding its Orviglance NDA for rare cancer conditions, indicating the application was not approved in its current form.

Outcome Details

Complete Response Letter received from FDA

Importance:8/10
Sentiment:
-0.80
FDACRLNDAoncologyrare cancer
Related Companies

Read the original article

Published by Drugs.com New Drug Applications on July 3, 2026 8:07 PM

Read Original